Chemomab Therapeutics (CMMB) Income Statement (2019 - 2023)
Income Statement report data from Mar 31, 2019 to Mar 31, 2023 for Chemomab Therapeutics (CMMB).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||||
Research And Development | 6.89M (+16.78%) | 5.90M (+8.86%) | 5.42M (+86.25%) | 2.91M (+5.82%) | 2.75M (+15.55%) | 2.38M (+59.73%) | 1.49M (+13.74%) | 1.31M (+12.93%) | 1.16M (-7.20%) | 1.25M (+21.36%) | 1.03M (+21.18%) | 850K (-45.16%) | 1.55M (+50.49%) | 1.03M (-81.51%) | 5.57M (+115.89%) | 2.58M (-37.68%) | 4.14M |
Selling General And Administrative | 2.16M (-21.45%) | 2.75M (-4.84%) | 2.89M (-13.47%) | 3.34M (+29.46%) | 2.58M (-2.27%) | 2.64M (+88.57%) | 1.40M (-3.45%) | 1.45M (+168.52%) | 540K (-21.74%) | 690K (+263.16%) | 190K (-24.00%) | 250K (+66.67%) | 150K (-88.37%) | 1.29M (-24.56%) | 1.71M (-12.76%) | 1.96M (+51.94%) | 1.29M |
Operating Expenses | 9.05M (+4.75%) | 8.64M (+3.85%) | 8.32M (+33.12%) | 6.25M (+17.48%) | 5.32M (+5.98%) | 5.02M (+73.70%) | 2.89M (+5.09%) | 2.75M (+61.76%) | 1.70M (-12.37%) | 1.94M (+57.72%) | 1.23M (+11.82%) | 1.10M (-35.29%) | 1.70M (-69.96%) | 5.66M (-22.15%) | 7.27M (+60.13%) | 4.54M (-16.39%) | 5.43M |
Depreciation And Amortization | 20K (-60.00%) | 50K | - | - | 10K (-66.67%) | 30K | - | - | 10K (-50.00%) | 20K | - | - | 10K (-96.15%) | 260K | - | - | 20K |
Operating Income | |||||||||||||||||
Ebit | -8.73M (+5.69%) | -8.26M (+2.23%) | -8.08M (+20.06%) | -6.73M (+31.96%) | -5.10M (+1.19%) | -5.04M (+69.70%) | -2.97M (+7.22%) | -2.77M (+62.94%) | -1.70M (-12.82%) | -1.95M (+59.84%) | -1.22M (+12.96%) | -1.08M (-36.09%) | -1.69M (-69.82%) | -5.60M (-21.90%) | -7.17M (+61.49%) | -4.44M (-55.20%) | -9.91M |
EBITDA | -8.72M (+6.08%) | -8.22M (+1.73%) | -8.08M (+20.06%) | -6.73M (+32.22%) | -5.09M (+1.60%) | -5.01M (+68.69%) | -2.97M (+7.22%) | -2.77M (+62.94%) | -1.70M (-11.92%) | -1.93M (+58.20%) | -1.22M (+12.96%) | -1.08M (-36.09%) | -1.69M (-68.35%) | -5.34M (-25.52%) | -7.17M (+61.49%) | -4.44M (-55.11%) | -9.89M |
Other Income / Expenses | |||||||||||||||||
Other Non Operating Income | - | 350K | - | - | - | -110.00K | - | - | - | - | - | - | - | - | - | - | - |
Net Income | |||||||||||||||||
Income Before Tax | -8.73M (+5.69%) | -8.26M (+2.23%) | -8.08M (+20.06%) | -6.73M (+31.96%) | -5.10M | 18M | -2.97M (+7.22%) | -2.77M | - | 5.95M | - | - | - | 27M | - | - | - |
Income Tax Expense | 20K (+100.00%) | 10K | - | -540.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -8.75M (+5.80%) | -8.27M (+2.35%) | -8.08M (+30.53%) | -6.19M (+21.37%) | -5.10M (+1.19%) | -5.04M (+69.70%) | -2.97M (+7.22%) | -2.77M (+62.94%) | -1.70M (-12.82%) | -1.95M (+59.84%) | -1.22M (+12.96%) | -1.08M (-36.09%) | -1.69M (-69.82%) | -5.60M (-21.90%) | -7.17M (+61.49%) | -4.44M (-55.20%) | -9.91M |
Net Income | -8.75M (+5.80%) | -8.27M (+2.35%) | -8.08M (+30.53%) | -6.19M (+21.37%) | -5.10M (+1.19%) | -5.04M (+69.70%) | -2.97M (+7.22%) | -2.77M (+62.94%) | -1.70M (-12.82%) | -1.95M (+59.84%) | -1.22M (+12.96%) | -1.08M (-36.09%) | -1.69M (-69.82%) | -5.60M (-21.90%) | -7.17M (+61.49%) | -4.44M (-55.20%) | -9.91M |
Comprehensive Income Net Of Tax | - | - | - | - | - | - | - | - | - | - | - | - | - | 27M | - | - | - |